$GLUE

Monte Rosa Therapeutics, Inc.

CIK:0001826457|SEC Filings

Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Collaboration Revenue	$ 8,968	$ 23,194	$ 13,178	$ 108,123
Operating expenses:
Research and development	47,964	30,653	92,033	62,843
General and administrative	10,134	8,095	20,309	16,798
Total operating expenses	58,098	38,748	112,342	79,641
(Loss) income from operations	(49,130)	(15,554)	(99,164)	28,482
Other income:
Interest income	5,916	3,068	11,507	6,507
Foreign currency exchange gain	25	1,390	17	1,563
Gain on disposal of property and equipment	0	0	0	59
Total other income	5,941	4,458	11,524	8,129
Net (loss) income before income taxes	(43,189)	(11,096)	(87,640)	36,611
Income tax provision	(208)	(1,199)	(260)	(2,021)
Net (loss) income	(43,397)	(12,295)	(87,900)	34,590
Comprehensive loss (income):
Provision for pension benefit obligation	54	53	109	101
Unrealized loss on available-for-sale securities	(473)	(97)	(1,447)	(118)
Comprehensive (loss) income	$ (43,816)	$ (12,339)	$ (89,238)	$ 34,573
(Loss) earnings per share:
Basic	$ (0.43)	$ (0.15)	$ (0.87)	$ 0.42
Diluted	$ (0.43)	$ (0.15)	$ (0.87)	$ 0.42
Weighted average number of shares outstanding:
Basic	101,478,945	82,186,768	100,685,824	82,167,849
Diluted	101,478,945	82,186,768	100,685,824	82,890,063

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities:
Net loss	$ (87,900)	$ 34,590
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation expense	11,919	10,192
Depreciation	3,943	4,173
Net accretion of discounts/premiums on marketable securities	(1,960)	(1,766)
Gain on disposal of property and equipment	0	(59)
Changes in operating assets and liabilities
Collaboration receivable	7,000	0
Other receivables	(320)	(2,196)
Prepaid expenses and other assets	(1,581)	(1,713)
Accounts payable	2,884	(11,976)
Accrued expenses and other current liabilities	(1,502)	(5,077)
Defined benefit plan liability	85	957
Right-of-use assets and operating lease liabilities	(874)	(427)
Deferred revenue	(13,177)	(106,910)
Net cash used in operating activities	(81,483)	(80,212)
Cash flows from investing activities:
Purchases of property and equipment	(6,591)	(3,282)
Purchases of marketable securities	(408,071)	(157,047)
Proceeds from maturities of marketable securities	124,805	85,424
Net cash used in investing activities	(289,857)	(74,905)
Cash flows from financing activities:
Proceeds from exercise of employee stock options	7,122	14
Proceeds from underwritten public offering, net of underwriter's commission of $20,700	324,300	0
Payment of offering costs	(487)	0
Proceeds from employee stock purchase plan	611	365
Net cash provided by financing activities	331,546	379
Net decrease in cash, cash equivalents and restricted cash	(39,794)	(154,738)
Cash, cash equivalents and restricted cash—beginning of period	134,837	229,117
Cash, cash equivalents and restricted cash-end of period	95,043	74,379
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents	90,104	69,429
Restricted cash	4,939	4,950
Total cash, cash equivalents and restricted cash	95,043	74,379
Supplemental disclosure of noncash items
Purchases of property and equipment in accounts payable and accrued expenses	$ 1,450	$ 450

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 90,104	$ 129,883
Marketable securities	531,000	247,221
Collaboration receivable	0	7,000
Other receivables	4,920	4,600
Prepaid expenses and other current assets	5,382	4,481
Total current assets	631,406	393,185
Property and equipment, net	29,932	25,986
Operating lease right-of-use assets	24,056	24,386
Restricted cash	4,939	4,954
Other long-term assets	828	148
Total assets	691,161	448,659
Current liabilities:
Accounts payable	7,152	3,550
Accrued expenses and other current liabilities	25,773	26,694
Current deferred revenue	22,103	29,571
Current portion of operating lease liability	4,630	4,397
Total current liabilities	59,658	64,212
Deferred revenue, net of current	105,623	111,332
Defined benefit plan liability	5,242	5,265
Operating lease liability, net of current	33,357	34,794
Total liabilities	203,880	215,603
Commitments and contingencies (Note 8)
Stockholders' equity
Preferred stock, $0.0001 par value, 10,000,000 shares authorized	0	0
Common stock, $0.0001 par value 500,000,000 shares authorized, 85,226,427 and 65,543,723 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	9	7
Additional paid-in capital	1,057,551	714,090
Accumulated other comprehensive loss	(5,165)	(3,827)
Accumulated deficit	(565,114)	(477,214)
Total stockholders' equity	487,281	233,056
Total liabilities and stockholders' equity	$ 691,161	$ 448,659